Breaking AI & Tech News Analyzed

Marine expert Richard Land leads a 2026 effort to release more than 15 million juvenile oysters into the North Sea off Orkney, aiming to rebuild historic beds and spark a trophic cascade of climate and ecological benefits.The project, backed by the Green Britain Foundation, the Nature Restoration Fund, Marine Fund Scotland and North Bay Innovations, employs a novel on‑shore rearing technique that cultivates oysters on calcium‑carbonate‑enriched plates before deploying them on long lines at sea.According to Richard Land, the initiative will not only aid fish stocks but also support sea mammals, seabirds and the broader marine environment. He describes the scheme as a blueprint for wider oyster reintroduction across the UK and European waters.Historical oyster beds once covered areas the size of Wales in the North Sea. Over‑exploitation during the Industrial Revolution—Londoners alone ate an estimated 700 million oysters between 1840‑1850—combined with pollution, climate change and habitat removal, led to a “negative cascade” that devastated marine ecosystems.Researchers estimate the new 100‑hectare (247‑acre) reef could sequester up to 76 tonnes of CO₂ annually. Project backer Dale Vince notes that once natural spawning is re‑established, carbon capture could exceed this figure by over 1,000‑fold after about 15 years.Alistair Carmichael, Liberal Democrat MP for Orkney and Shetland, welcomed the plan, highlighting its dual promise of wildlife recovery and carbon sequestration. Philine Zu Ermgassen of the University of Edinburgh stressed that hatchery innovations are essential to produce sufficient local‑genetic stock for successful restoration.By re‑introducing native oysters, the scheme aims to create complex reefs that host scallops, molluscs, algae, seaweeds and numerous invertebrates, thereby revitalising marine biodiversity while contributing to climate mitigation.

New research indicates that individuals carrying the red‑hair allele have been evolutionary winners in Europe for more than 10,000 years. The study, led by Harvard scientists, examined DNA from nearly 16,000 ancient remains and over 6,000 living Europeans, providing robust proof that human biology continues to evolve long after farming began. Researchers identified 479 genetic variants that show clear signs of positive selection. Among these are genes linked to red hair and fair skin, as well as variants that affect susceptibility to coeliac disease, diabetes risk, baldness and rheumatoid arthritis. The authors suggest that the advantage of red hair may stem from its association with lighter skin, which enhances vitamin D synthesis in low‑sunlight environments—a crucial benefit for early European farmers. Prior to this work, only about 21 traits had been documented as having risen through natural selection, such as lactase persistence. The scarcity of earlier examples had led some to argue that directional selection was rare after modern humans left Africa. By leveraging an unprecedented volume of ancient genomic data and advanced computational methods, the team demonstrated that selection pressures intensified during the transition from hunter‑gatherer societies to agricultural ones, reshaping hundreds of genes across West Eurasia. "With these new techniques and the sheer scale of ancient DNA, we can now observe how selection sculpted our biology in near real‑time," said Dr. Ali Akbari, the study’s first author. Beyond vitamin D, the rise of certain disease‑related alleles poses intriguing puzzles. A mutation that heightens the risk of coeliac disease emerged around 4,000 years ago and has steadily increased, implying that carriers may have enjoyed other survival advantages despite the autoimmune threat. Similarly, the immune‑regulating gene TYK2, which markedly raises tuberculosis susceptibility, grew in frequency between 9,000 and 3,000 years ago before declining, hinting at a complex balance between pathogen defense and disease risk. The analysis also uncovered negative selection against genetic profiles that promote a high body‑fat percentage, supporting the classic “thrifty genes” hypothesis: traits advantageous for storing energy during scarce hunter‑gatherer periods became detrimental once agriculture ensured a steadier food supply. "This work lets us assign both place and time to the forces that have shaped us," noted Prof. David Reich, senior author and Harvard Medical School geneticist. While the findings are confined to West Eurasian populations, they raise broader questions about whether similar evolutionary dynamics occurred elsewhere. The full study appears in Nature.

A recent court of appeal decision suggesting it's impossible to determine which identical twin fathered a child has sparked controversy among genetics experts. Prof Michael Krawczak from Kiel University, Germany, argues that this is not the case. According to Krawczak, the germ cells of monozygotic twins differ with sufficient probability and to a sufficient degree to allow their respective children to be clearly assigned to either of them using molecular genetic techniques.Krawczak and his colleagues first proposed this approach in 2012 and demonstrated its practical feasibility in 2018. While the required molecular genetic testing is costly, currently in the five-figure range, Krawczak questions whether these costs would be a significant enough barrier to preclude genetic testing, given the potential consequences of inaction for those involved.The court's assertion that it was "not possible" to determine paternity in such cases is therefore disputed. Krawczak's comments highlight the potential for genetic testing to resolve paternity disputes in cases involving monozygotic twins, offering a solution to a complex and sensitive issue.

Up early on a remarkable day, the moon still visible in the morning sky, evoking a sense of wonder with the knowledge of four humans having traveled further from Earth than anyone in history. The author seeks Easter tranquility by the sea in the Ventnor Undercliff, Isle of Wight, where on a clear day, France seems within sight.Sitting on the terrace, taking in the view, the author notices a fast, lithe, slender movement. A wall lizard, camouflaged against the olive tree bark, is basking in the warmest day of the year. Its coloring features olive, muted grey, brown, and yellow flank stripes.The origin of the well-established wall lizard population in the area is disputed, with theories including shipwreck survivors, wild animals at the northernmost end of their range, or introduced by collectors in the late 19th century. A genetic study suggests their origins are in Italy, in the middle of their European range.The Undercliff's microclimate suits the lizards' lifestyle, with south-facing terraces, scrubby plants, and handy crevices. The lizard's bold behavior leads it to dash straight towards the author, stopping inches away, seemingly unafraid and possibly indignant. After a moment, it scampers past without acknowledgment, and both the lizard and the author continue their day.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

A comprehensive study from Denmark has concluded that taking acetaminophen, commonly known as Tylenol, during pregnancy has no effect on later autism diagnoses in children. The research, which utilized Denmark's robust national healthcare system to track more than 1.5 million children born between 1997 and 2022, including 31,098 children who were exposed to Tylenol in utero, found no significant link between Tylenol use and autism. The study's findings contradict claims made by the Trump administration, which had suggested that Tylenol use during pregnancy was a major cause of autism in children. This led to a notable 16% drop in Tylenol orders for pregnant women in emergency rooms following the announcement. However, the new study provides reassurance that Tylenol is safe to use during pregnancy for pain relief and fever reduction. According to the study, autism was diagnosed in 1.8% of children who were exposed to Tylenol and 3% of those who weren’t. A similar 2024 study in Sweden found a marginal link that disappeared after considering siblings, suggesting that autism is strongly genetic. Health officials had previously announced a label change for acetaminophen, warning of a potential link to autism, which has now been called into question. Experts, such as Jeremy Faust, an emergency physician at Mass General Brigham and a health services researcher at Harvard Medical School, have noted that the words of health officials can significantly affect behavior, as evidenced by the drop in Tylenol orders. However, Faust also emphasized that Tylenol remains one of the safest options for pain control and fever reduction during pregnancy.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

The UK's reliance on glyphosate, a widely used herbicide, has come under fire from campaigners who argue that its use has spiralled out of control. Glyphosate, known for its effectiveness in killing weeds, has been linked to various health risks, including cancer, and environmental damage.Originally pioneered by Scottish farmers in the 1980s to dry crops before harvest, the use of glyphosate has expanded globally. In the UK, over 2,200 tonnes of glyphosate were applied in 2024, with more than half used on wheat and other cereals. This represents a 10-fold increase in usage over the past three decades.Despite the World Health Organization classifying glyphosate as 'probably carcinogenic to humans' in 2015, its use has remained high. Bayer, the manufacturer, maintains that its herbicides do not cause cancer, but this stance is contested by many health and environmental organizations.Campaigners, including Nick Mole of Pesticide Action Network UK, are urging the government to phase out and ultimately ban glyphosate, citing its links to a range of cancers and other life-threatening diseases, as well as its impact on the environment. They argue that safer, more sustainable alternatives are available and should be adopted by farmers and local councils.However, some agricultural experts, like Helen Metcalfe of Rothamsted Research, suggest that glyphosate is used differently in the UK compared to the US, where genetically modified crops are involved. The shift towards 'regenerative' farming practices has contributed to the increased use of glyphosate, as it helps protect soil health and prevent erosion.The debate over glyphosate's safety and environmental impact continues, with the EU banning its use in pre-harvest desiccation in 2023 due to concerns about food accumulation. In the US, Bayer has offered $7.25bn to settle lawsuits alleging that Roundup, which contains glyphosate, can cause cancer. The UK government maintains that pesticide use is strictly regulated and only approved if it does not harm human or animal health or the environment.

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.